Trials / Completed
CompletedNCT00293163
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the likelihood of keloid and scar formation, pigmentation disorders and hypersensitivity reactions in patients with skin of color undergoing correction of facial soft tissue contour deficiencies with Hylaform, Hylaform Plus or Captique.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Hylaform, Hylaform Plus (hylan B gel) |
Timeline
- Start date
- 2006-02-01
- Completion
- 2006-10-01
- First posted
- 2006-02-17
- Last updated
- 2015-03-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00293163. Inclusion in this directory is not an endorsement.